Novavax, Inc. announced that European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for its COVID-19 vaccine, which will be marketed in the EU as Nuvaxovid.   “Today’s announcement from EMA brings Novavax another step closer to our goal of ensuring broad global access to our protein-based COVID-19 vaccine across Europe,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “Novavax looks ...